Home > Journals > Minerva Ophthalmology > Past Issues > Minerva Oftalmologica 2001 March-June;43(1-2) > Minerva Oftalmologica 2001 March-June;43(1-2):35-42

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Share

 

REVIEWS   

Minerva Oftalmologica 2001 March-June;43(1-2):35-42

Copyright © 2001 EDIZIONI MINERVA MEDICA

language: Italian

Neuroprotection: the next step in glaucoma therapy

Rossi S., D¹Amico M., Mazzeo F., Vitelli M., Di Filippo C.


PDF


Scientific researches are aimed to reduce the glaucoma by means of neuroprotection since an optical nerve damage could determine visual loss. Actually, there are neuroprotective drugs such as i) blood flow enhancers such as Ca2+ blockers; ii) glutamate inhibitors; iii) nitric oxide inhibitors; iv) free radical scavengers/antioxidant. Moreover, experimental studies have shown that growth factors such as bFGF (basic fibroblastic growth factor), brain neurotrophic factor (BDNF), neutrophin-4 and ciliary neurotrophic (CNTF) greatly reduce retinal ganglion cell death rates after axotomy. Recent molecular genetic studies have identified the bax and bad genes as stimulators and bcl-x and bcl-2 genes as suppressor of retinal glanglion cell apoptosis.

top of page